2496 — Wuhan YZY Biopharma Co Income Statement
0.000.00%
Last trade - 00:00
- HK$1.45bn
- HK$1.33bn
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 134 | 186 | 189 |
Operating Profit | -134 | -186 | -189 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -149 | -189 | -192 |
Provision for Income Taxes | |||
Net Income After Taxes | -149 | -189 | -192 |
Net Income Before Extraordinary Items | |||
Net Income | -149 | -189 | -192 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -149 | -189 | -192 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.753 | -0.918 | -0.902 |